<ul><li>Paris-based kyron.bio secures €5.5 million Seed funding to address drug efficacy and safety concerns related to glycan control in drug development.</li><li>HCVC led the funding round with participation from Verve Ventures, Entrepreneur First, Saras Capital, and other angel investors.</li><li>kyron.bio aims to utilize precision glycosylation in drug design, leveraging proprietary technology for better antibody therapeutics in various diseases.</li><li>The funding will be used to advance kyron.bio's glycan-engineering platform, expand the team, and support preclinical studies.</li></ul>

Paris-based kyron.bio secures €5.5 million to tackle drug efficiency and safety

Discover more